Identification and Characterization of an Irreversible Inhibitor of CDK2-Reference-Cited by-同舟云学术

Identification and Characterization of an Irreversible Inhibitor of CDK2

Published:2015-09 Issue:9 Volume:22 Page:1159-1164
ISSN:1074-5521
Container-title:Chemistry & Biology
language:en
Short-container-title:Chemistry & Biology

Author:

Anscombe Elizabeth,Meschini Elisa,Mora-Vidal Regina,Martin Mathew P.,Staunton David,Geitmann Matthis,Danielson U. Helena,Stanley Will A.,Wang Lan Z.,Reuillon Tristan,Golding Bernard T.,Cano Celine,Newell David R.,Noble Martin E.M.,Wedge Stephen R.,Endicott Jane A.,Griffin Roger J.

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Biology,Molecular Medicine,General Medicine,Biochemistry

Reference25 articles.

1. Irreversible protein kinase inhibitors: balancing the benefits and risks;Barf;J. Med. Chem.,2012

2. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases;Brown;Nat. Cell Biol.,1999

3. The CCP4 suite: programs for protein crystallography;CCP4;Acta Crystallogr. D Biol. Crystallogr.,1994

4. Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma;Cheng;Proc. Natl. Acad. Sci. USA,2012

5. The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling;Dar;Annu. Rev. Biochem.,2011

Cited by 94 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Development of CDK2 Inhibitors as Anticancer Drugs: An Update (2015–2023);Pharmaceutical Fronts;2024-09-03

2. Rationally designed BCR-ABL kinase inhibitors for improved leukemia treatment via covalent and pro-/dual-drug targeting strategies;Journal of Advanced Research;2024-09

3. Targeting cyclin-dependent kinases: From pocket specificity to drug selectivity;European Journal of Medicinal Chemistry;2024-09

4. Inhibitors and PROTACs of CDK2: challenges and opportunities;Expert Opinion on Drug Discovery;2024-07-12

5. Histidine-Covalent Stapled Alpha-Helical Peptides Targeting hMcl-1;Journal of Medicinal Chemistry;2024-05-02